BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

685 related articles for article (PubMed ID: 25689978)

  • 1. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria.
    Yao FY; Mehta N; Flemming J; Dodge J; Hameed B; Fix O; Hirose R; Fidelman N; Kerlan RK; Roberts JP
    Hepatology; 2015 Jun; 61(6):1968-77. PubMed ID: 25689978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
    Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
    World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation.
    Yao FY; Hirose R; LaBerge JM; Davern TJ; Bass NM; Kerlan RK; Merriman R; Feng S; Freise CE; Ascher NL; Roberts JP
    Liver Transpl; 2005 Dec; 11(12):1505-14. PubMed ID: 16315294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are There Upper Limits in Tumor Burden for Down-Staging of Hepatocellular Carcinoma to Liver Transplant? Analysis of the All-Comers Protocol.
    Sinha J; Mehta N; Dodge JL; Poltavskiy E; Roberts J; Yao F
    Hepatology; 2019 Oct; 70(4):1185-1196. PubMed ID: 30779440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.
    Mehta N; Frenette C; Tabrizian P; Hoteit M; Guy J; Parikh N; Ghaziani TT; Dhanasekaran R; Dodge JL; Natarajan B; Holzner ML; Frankul L; Chan W; Fobar A; Florman S; Yao FY
    Gastroenterology; 2021 Nov; 161(5):1502-1512. PubMed ID: 34331914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation.
    Sharr WW; Chan SC; Lo CM
    Transplantation; 2014 Apr; 97 Suppl 8():S10-7. PubMed ID: 24849822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphological features of advanced hepatocellular carcinoma as a predictor of downstaging and liver transplantation: an intention-to-treat analysis.
    Barakat O; Wood RP; Ozaki CF; Ankoma-Sey V; Galati J; Skolkin M; Toombs B; Round M; Moore W; Mieles L
    Liver Transpl; 2010 Mar; 16(3):289-99. PubMed ID: 20209588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of Successful Downstaging of Hepatocellular Carcinoma Outside Milan Criteria.
    Murali AR; Romero-Marrero C; Miller C; Aucejo F; Levitin A; Gill A; McLennan G; Karuppasamy K; Zein NN; Lopez R; Menon KV
    Transplantation; 2016 Nov; 100(11):2391-2397. PubMed ID: 27780187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit of downsizing hepatocellular carcinoma in a liver transplant population.
    Jang JW; You CR; Kim CW; Bae SH; Yoon SK; Yoo YK; Kim DG; Choi JY
    Aliment Pharmacol Ther; 2010 Feb; 31(3):415-23. PubMed ID: 19821808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downstaging hepatocellular carcinoma: A systematic review and pooled analysis.
    Parikh ND; Waljee AK; Singal AG
    Liver Transpl; 2015 Sep; 21(9):1142-52. PubMed ID: 25981135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor biology and pre-transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation.
    Kim PT; Onaca N; Chinnakotla S; Davis GL; Jennings LW; McKenna GJ; Ruiz RM; Levy MF; Goldstein R; Klintmalm GB
    Clin Transplant; 2013; 27(2):311-8. PubMed ID: 23351129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients with non-[18 F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation.
    Kornberg A; Küpper B; Tannapfel A; Büchler P; Krause B; Witt U; Gottschild D; Friess H
    Liver Transpl; 2012 Jan; 18(1):53-61. PubMed ID: 21850692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Liver Transplant on Long-term Disease-Free Survival in Children With Hepatoblastoma and Hepatocellular Cancer.
    Pham TA; Gallo AM; Concepcion W; Esquivel CO; Bonham CA
    JAMA Surg; 2015 Dec; 150(12):1150-8. PubMed ID: 26308249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients With Hepatocellular Carcinoma Presenting Beyond Milan Criteria.
    Kardashian A; Florman SS; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Aucejo F; Tevar AD; Humar A; Verna EC; Halazun KJ; Chapman WC; Vachharajani N; Hoteit M; Levine MH; Nguyen MH; Melcher ML; Langnas AN; Carney CA; Mobley C; Ghobrial M; Amundsen B; Markmann JF; Sudan DL; Jones CM; Berumen J; Hemming AW; Hong JC; Kim J; Zimmerman MA; Nydam TL; Rana A; Kueht ML; Fishbein TM; Markovic D; Busuttil RW; Agopian VG
    Hepatology; 2020 Dec; 72(6):2014-2028. PubMed ID: 32124453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver Transplantation for Advanced Hepatocellular Carcinoma after Downstaging Without Up-Front Stage Restrictions.
    Chapman WC; Garcia-Aroz S; Vachharajani N; Fowler K; Saad N; Lin Y; Wellen J; Tan B; Khan AS; Doyle MB
    J Am Coll Surg; 2017 Apr; 224(4):610-621. PubMed ID: 28069527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing.
    Mehta N; Sarkar M; Dodge JL; Fidelman N; Roberts JP; Yao FY
    Liver Transpl; 2016 Feb; 22(2):178-87. PubMed ID: 26479422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria.
    Kim Y; Stahl CC; Makramalla A; Olowokure OO; Ristagno RL; Dhar VK; Schoech MR; Chadalavada S; Latif T; Kharofa J; Bari K; Shah SA
    Surgery; 2017 Dec; 162(6):1250-1258. PubMed ID: 29033224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma downstaging in liver transplantation.
    Yu CY; Ou HY; Huang TL; Chen TY; Tsang LL; Chen CL; Cheng YF
    Transplant Proc; 2012 Mar; 44(2):412-4. PubMed ID: 22410030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.